Intra-Diverticular Bladder Tumours: How to Manage Rationally

Mohammed Lotfi Amer, H. Mumtaz, B. Russell, Jason Gan, Z. Rehman, Rajesh M. Nair, R. Thurairaja, Muhammad S. Khan
{"title":"Intra-Diverticular Bladder Tumours: How to Manage Rationally","authors":"Mohammed Lotfi Amer, H. Mumtaz, B. Russell, Jason Gan, Z. Rehman, Rajesh M. Nair, R. Thurairaja, Muhammad S. Khan","doi":"10.48083/jclw6772","DOIUrl":null,"url":null,"abstract":"Objective To report changing practice in the management of intra-diverticular bladder tumours. Methods We undertook a review of all intra-diverticular bladder tumours in our prospectively maintained institutional database. Results A total of 28 patients (male = 27, female = 1) with a median age of 71 years (IQR 61 to 76) were diagnosed with intra-diverticular bladder tumours (IDBT) between March 2013 and February 2021. Fourteen had visible and 3 had non-visible haematuria, while 11 patients had lower urinary tract symptoms. Median axial diameter of the diverticula was 46 mm (IQR 35 to 69), and median neck diameter was 9 mm (IQR 7 to 11). All patients had CT-urography and 5 patients also had an MRI. Surgical treatment consisted of diverticulectomy (n = 11), diverticulectomy and ipsilateral ureteric reimplantation (n = 11), radical cystectomy and ileal conduit (n = 4), or radical cystectomy and orthotopic bladder (n = 2). Eleven patients had open procedures, and 17 had robotic assisted surgery. Final pathological stages were T0 (n = 2), Ta (n = 5), T1 (n = 7), T3a (n = 8) and T3b (n = 6). Twenty-four patients had urothelial carcinoma (including one nested variant and 4 with squamous differentiation) and 2 had small cell carcinoma. Three patients had neoadjuvant systemic chemotherapy, 2 had intravesical bacillus Calmette-Guerin (BCG) with mitomycin, and one had BCG monotherapy preoperatively. Five patients had adjuvant systemic chemotherapy while 7 had adjuvant intravesical therapies. Mean follow-up period was 37.8 months (±25.3). Mean recurrence-free survival was 61.5% (CI 45.7 to 77.4) and mean overall survival 71.6 % (CI 57.4 to 85.8). Ten patients (37%) died of cancer. Conclusion Management of intra-diverticular bladder tumours is evolving. Bladder-sparing approaches are gaining popularity. Robot-assisted diverticulectomy is preferable as it reduces the morbidity resulting from treatment.","PeriodicalId":21961,"journal":{"name":"Société Internationale d’Urologie Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Société Internationale d’Urologie Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48083/jclw6772","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To report changing practice in the management of intra-diverticular bladder tumours. Methods We undertook a review of all intra-diverticular bladder tumours in our prospectively maintained institutional database. Results A total of 28 patients (male = 27, female = 1) with a median age of 71 years (IQR 61 to 76) were diagnosed with intra-diverticular bladder tumours (IDBT) between March 2013 and February 2021. Fourteen had visible and 3 had non-visible haematuria, while 11 patients had lower urinary tract symptoms. Median axial diameter of the diverticula was 46 mm (IQR 35 to 69), and median neck diameter was 9 mm (IQR 7 to 11). All patients had CT-urography and 5 patients also had an MRI. Surgical treatment consisted of diverticulectomy (n = 11), diverticulectomy and ipsilateral ureteric reimplantation (n = 11), radical cystectomy and ileal conduit (n = 4), or radical cystectomy and orthotopic bladder (n = 2). Eleven patients had open procedures, and 17 had robotic assisted surgery. Final pathological stages were T0 (n = 2), Ta (n = 5), T1 (n = 7), T3a (n = 8) and T3b (n = 6). Twenty-four patients had urothelial carcinoma (including one nested variant and 4 with squamous differentiation) and 2 had small cell carcinoma. Three patients had neoadjuvant systemic chemotherapy, 2 had intravesical bacillus Calmette-Guerin (BCG) with mitomycin, and one had BCG monotherapy preoperatively. Five patients had adjuvant systemic chemotherapy while 7 had adjuvant intravesical therapies. Mean follow-up period was 37.8 months (±25.3). Mean recurrence-free survival was 61.5% (CI 45.7 to 77.4) and mean overall survival 71.6 % (CI 57.4 to 85.8). Ten patients (37%) died of cancer. Conclusion Management of intra-diverticular bladder tumours is evolving. Bladder-sparing approaches are gaining popularity. Robot-assisted diverticulectomy is preferable as it reduces the morbidity resulting from treatment.
膀胱憩室内肿瘤:如何合理处理
目的探讨膀胱憩室内肿瘤的治疗方法。方法:我们在前瞻性维护的机构数据库中对所有憩室内膀胱肿瘤进行了回顾。结果2013年3月至2021年2月,共有28例患者被诊断为憩室内膀胱肿瘤(IDBT),其中男性27例,女性1例,中位年龄71岁(IQR 61 ~ 76岁)。14例可见血尿,3例不可见血尿,11例有下尿路症状。憩室中轴径46 mm (IQR 35 ~ 69),颈中径9 mm (IQR 7 ~ 11)。所有患者行ct尿路造影,5例患者行MRI。手术治疗包括憩室切除术(n = 11)、憩室切除术+同侧输尿管再植(n = 11)、根治性膀胱切除术+回肠导管(n = 4)或根治性膀胱切除术+原位膀胱(n = 2)。11例患者采用开腹手术,17例患者采用机器人辅助手术。最终病理分期为T0 (n = 2)、Ta (n = 5)、T1 (n = 7)、T3a (n = 8)、T3b (n = 6)。24例患者为尿路上皮癌(其中巢状变异1例,鳞状分化4例),2例为小细胞癌。3例患者行新辅助全身化疗,2例患者行膀胱内卡介苗联合丝裂霉素治疗,1例患者术前行卡介苗单药治疗。5例患者行辅助全身化疗,7例行辅助膀胱内化疗。平均随访37.8个月(±25.3个月)。平均无复发生存率为61.5% (CI 45.7 ~ 77.4),平均总生存率为71.6% (CI 57.4 ~ 85.8)。10名患者(37%)死于癌症。结论膀胱憩室内肿瘤的治疗方法在不断发展。保留膀胱的方法越来越受欢迎。机器人辅助憩室切除术是可取的,因为它减少了治疗引起的发病率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信